人类男性不育单基因病因系统综述:2020年更新
该综述由国际男性不育基因组学联盟系统评估截至2020年7月1日的证据,鉴定出120个基因与104种不育表型存在中等、强或确定性关联,较2019年增加33%。作者建议更新遗传检测指南,采用外显子测序并扩大检测患者群体。
要点
- 120个基因与104种男性不育表型存在中等及以上临床有效性关联。
- 现有男性不育遗传检测指南基于25年前研究,亟需更新。
- 联盟推荐采用外显子测序或至少检测本综述验证的基因。
核心结论
- 系统综述鉴定出120个基因与104种男性不育表型存在中等、强或确定性关联,较2019年增加33%。
- 现有遗传检测指南基于25年前研究,亟需更新以纳入新证据。
研究设计与样本
- 按照PRISMA指南检索截至2020年7月1日的PubMed英文文献,关键词为「男性不育」联合「遗传学」。
- 采用标准化评分方法评估实验质量、患者表型评估及功能证据,将基因-疾病关系分为无证据、有限、中等、强或确定五类。
- 变体按ACMG-AMP指南重新分类并记录于imigc.org表格。
主要发现
- 共鉴定120个基因与104种不育表型存在中等、强或确定性关联。
- 约4%的不育男性可诊断遗传病因,但60-70%仍为不明原因。
关键数值与推荐
- 基因-疾病关系临床有效性分为五类:无证据、有限、中等、强、确定。
- 120个基因被评定为中等、强或确定性关联。
临床怎么用
- 联盟推荐采用外显子测序,或至少对本综述验证的基因进行测序。
- 建议扩大推荐遗传检测的患者群体。
局限性
- 证据截至2020年7月1日,未纳入此后发表的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human male infertility has a notable genetic component, including well-established diagnoses such as Klinefelter syndrome, Y-chromosome microdeletions and monogenic causes. Approximately 4% of all infertile men are now diagnosed with a genetic cause, but a majority (60-70%) remain without a clear diagnosis and are classified as unexplained. This is likely in large part due to a delay in the field adopting next-generation sequencing (NGS) technologies, and the absence of clear statements from field leaders as to what constitutes a validated cause of human male infertility (the current paper aims to address this). Fortunately, there has been a significant increase in the number of male infertility NGS studies. These have revealed a considerable number of novel gene-disease relationships (GDRs), which each require stringent assessment to validate the strength of genotype-phenotype associations. To definitively assess which of these GDRs are clinically relevant, the International Male Infertility Genomics Consortium (IMIGC) has identified the need for a systematic review and a comprehensive overview of known male infertility genes and an assessment of the evidence for reported GDRs. OBJECTIVE AND RATIONALE: In 2019, the first standardised clinical validity assessment of monogenic causes of male infertility was published. Here, we provide a comprehensive update of the subsequent 1.5 years, employing the joint expertise of the IMIGC to systematically evaluate all available evidence (as of 1 July 2020) for monogenic causes of isolated or syndromic male infertility, endocrine disorders or reproductive system abnormalities affecting the male sex organs. In addition, we systematically assessed the evidence for all previously reported possible monogenic causes of male infertility, using a framework designed for a more appropriate clinical interpretation of disease genes. SEARCH METHODS: We performed a literature search according to the PRISMA guidelines up until 1 July 2020 for publications in English, using search terms related to 'male infertility' in combination with the word 'genetics' in PubMed. Next, the quality and the extent of all evidence supporting selected genes were assessed using an established and standardised scoring method. We assessed the experimental quality, patient phenotype assessment and functional evidence based on gene expression, mutant in-vitro cell and in-vivo animal model phenotypes. A final score was used to determine the clinical validity of each GDR, across the following five categories: no evidence, limited, moderate, strong or definitive. Variants were also reclassified according to the American College of Medical Genetics and Genomics-Association for Molecular Pathology (ACMG-AMP) guidelines and were recorded in spreadsheets for each GDR, which are available at imigc.org. OUTCOMES: The primary outcome of this review was an overview of all known GDRs for monogenic causes of human male infertility and their clinical validity. We identified a total of 120 genes that were moderately, strongly or definitively linked to 104 infertility phenotypes. WIDER IMPLICATIONS: Our systematic review curates all currently available evidence to reveal the strength of GDRs in male infertility. The existing guidelines for genetic testing in male infertility cases are based on studies published 25 years ago, and an update is far overdue. The identification of 104 high-probability 'human male infertility genes' is a 33% increase from the number identified in 2019. The insights generated in the current review will provide the impetus for an update of existing guidelines, will inform novel evidence-based genetic testing strategies used in clinics, and will identify gaps in our knowledge of male infertility genetics. We discuss the relevant international guidelines regarding research related to gene discovery and provide specific recommendations to the field of male infertility. Based on our findings, the IMIGC consortium recommend several updates to the genetic testing standards currently employed in the field of human male infertility, most important being the adoption of exome sequencing, or at least sequencing of the genes validated in this study, and expanding the patient groups for which genetic testing is recommended.
引用
- Houston BJ, Riera-Escamilla A, Wyrwoll MJ, et al. A systematic review of the validated monogenic causes of human male infertility: 2020 update and a discussion of emerging gene-disease relationships. Hum Reprod Update. 2021. PMID: 34498060. doi:10.1093/humupd/dmab030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。